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ABSTRACT
Background The most common spinocerebellar ataxias
(SCA)—SCA1, SCA2, SCA3, and SCA6—are caused by
(CAG)n repeat expansion. While the number of repeats
of the coding (CAG)n expansions is correlated with the
age at onset, there are no appropriate models that
include both affected and preclinical carriers allowing for
the prediction of age at onset.
Methods We combined data from two major European
cohorts of SCA1, SCA2, SCA3, and SCA6 mutation
carriers: 1187 affected individuals from the EUROSCA
registry and 123 preclinical individuals from the RISCA
cohort. For each SCA genotype, a regression model was
ﬁtted using a log-normal distribution for age at onset
with the repeat length of the alleles as covariates. From
these models, we calculated expected age at onset from
birth and conditionally that this age is greater than the
current age.
Results For SCA2 and SCA3 genotypes, the expanded
allele was a signiﬁcant predictor of age at onset
(−0.105±0.005 and −0.056±0.003) while for SCA1
and SCA6 genotypes both the size of the expanded and
normal alleles were signiﬁcant (expanded: −0.049
±0.002 and −0.090±0.009, respectively; normal:
+0.013±0.005 and −0.029±0.010, respectively).
According to the model, we indicated the median values
(90% critical region) and the expectancy (SD) of the
predicted age at onset for each SCA genotype according
to the CAG repeat size and current age.
Conclusions These estimations can be valuable in
clinical and research. However, results need to be
conﬁrmed in other independent cohorts and in future
longitudinal studies.
ClinicalTrials.gov, number NCT01037777 and
NCT00136630 for the French patients.
INTRODUCTION
Autosomal dominant cerebellar ataxias, also known
as spinocerebellar ataxias (SCA), are neurodegenera-
tive diseases that are clinically and genetically het-
erogeneous. Major advances have been made in the
understanding of their causes since the 1990s and
mutations in more than 20 genes have been identi-
ﬁed thus far to be responsible for different forms of
the disease. These mutations are comprised of con-
ventional mutations, non-coding nucleotide expan-
sions, and coding (CAG)n expansions.1 SCA1,
SCA2, Machado-Joseph or SCA3, SCA6, SCA7,
SCA12, SCA17, and dentatorubral-pallidoluysian
atrophy (DRPLA) are caused by (CAG)n repeat
expansions in the ATXN1, ATXN2, ATXN3,
CACNA1A, ATXN7, PPP2R2B, TBP, and ATN1
genes, respectively, and all lead to the expansion of
a polyglutamine tract in the corresponding proteins.
Repeat-associated non-ATG translation (RAN) of
polyglutamine tracts has also been observed in
SCA8 and may contribute to the disease process.2
All so-called polyglutamine ataxias share many
common features, including a negative relationship
between age at onset and the number of repeats in
the expansion, and a more severe disease with larger
expansions. The mean age at onset of symptoms for
SCA1, SCA2, SCA3, and SCA7 carriers is generally
in the third or fourth decade of life, but an average
of 20 years later for SCA6 carriers.3 The threshold
of CAG expansions, or the number of expansions
that determines disease carrier status, varies
between the different forms of SCA as do the
boundaries between what is considered an expanded
and normal size (overlapping in SCA1). In most
forms this threshold can be found around 40
repeats, except for in SCA6 where it is closer to 20.1
Gait ataxia is the ﬁrst symptom identiﬁed in the
majority of cases of these diseases. Globas et al4
have shown that only 12% of SCA1, 13% of SCA2,
15% of SCA3, and 24% of SCA6 patients have
other symptoms before the onset of gait ataxia.
Nevertheless, the onset and the phenotype may
differ considerably between two individuals with
the same genotype.5 Previous studies investigating
the relationship between CAG repeat length and
age at onset are of limited use in predicting the
mean age at onset, as they have relied on simple
linear correlations in patients and did not build pre-
dictive models that take into account information
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from clinically unaffected mutation carriers, thus creating a bias
favouring pathology. In another polyglutamine disease,
Huntington’s disease, similar modelling has been performed
using statistical models that elucidated the relationship between
CAG length and age at onset.6–8 In SCA, a similar approach was
used in the Cuban SCA2 population,9 although this approach
has not been repeated in other forms of SCA.
It is crucial that studies dealing with prediction of disease
onset include both affected individuals and preclinical indivi-
duals, which has not been the case in previous models. Ignoring
individuals who are free of disease symptoms, are the same age,
and have the same number of CAG repeats as affected indivi-
duals creates an artiﬁcial tendency towards earlier disease onset.
For the purposes of this study, we pooled genetic and age at
onset data of a large group of SCA1, SCA2, SCA3, and SCA6
patients from the European EUROSCA registry with data of
clinically unaffected carriers of SCA1, SCA2, SCA3, and SCA6
mutations from the RISCA study. The EUROSCA registry was
established in 2004 to collect core data of European SCA
patients. RISCA is a prospective, multicentric, multinational,
observational cohort of clinically unaffected at-risk individuals
for SCA1, SCA2, SCA3, and SCA6 (ie, ﬁrst degree relatives of
patients with one of these diseases).10
PATIENTS AND METHODS
Patients
Two groups of individuals were included: affected patients
(EUROSCA registry) and preclinical mutation carriers (RISCA
cohort). The EUROSCA registry includes individuals with any
form of spinocerebellar ataxia (SCA) from 17 European centres.
For the current study, we selected 1187 patients with a positive
molecular genetic test for SCA1, SCA2, SCA3 or SCA6, geno-
typed at a central laboratory, and with information available on
age at onset of the disease (317 SCA1, 308 SCA2, 399 SCA3,
and 163 SCA6) and, when possible, a SARA (Scale for the
Assessment and Rating of Ataxia, with a maximal score of 40
indicating a very severe cerebellar ataxia) score ≥3.10 Patients
were included in the database with age at onset as indicated by
self-report during their examination by the neurologist, and as
indicated in their medical records. Disease onset was deﬁned by
the onset of gait difﬁculties, as this is the most frequent ﬁrst
symptom. Data were obtained from patients by personal inter-
view. Information obtained by interview was then compared to
that from medical records, if available.
The RISCA cohort included individuals at-risk for SCA from
14 European centres.11 These included adult individuals, chil-
dren or siblings of an individual with SCA1, SCA2, SCA3 or
SCA6. Absence of ataxia was deﬁned as having a score on the
SARA scale <3. All individuals were genotyped in the same
central laboratory as the EUROSCA registry, and of the 264
individuals included with DNA available, 123 (47%) were car-
riers of a disease-causing expansion (50 SCA1, 31 SCA2, 26
SCA3, and 16 SCA6). For these preclinical mutation carriers,
the age at examination was recorded.
All participants signed informed consent documents approved
by institutional review boards and the local ethics committee.
Genotypes
Blood samples to obtain DNA for genetic testing were taken
from all study participants including those who had already
undergone preclinical genetic testing. All genetic tests were per-
formed at the Institute of Medical Genetics and Applied
Genomics (Tübingen, Germany) using established and standar-
dised methods.
For the RISCA cohort, the genetic tests were done anonym-
ously under an arrangement that guaranteed that results were
not disclosed to study participants, clinical investigators or
anyone else except the statistician’s team (STdM and ID-G).
However, all study participants were offered genetic counselling
with an open preclinical testing procedure according to estab-
lished clinical standards.
For both cohorts, we deﬁned the pathological thresholds as a
CAG repeat expansion of more than 39 repeats in SCA1, more
than 31 repeats in SCA2, more than 47 repeats in SCA3, and
more than 20 repeats in SCA6.
Prediction of age at onset
Statistical model
The prediction of age at onset was achieved using a statistical
model to relate the age at onset of an individual with his geno-
type. As our ﬁnal sample included some individuals who had
not yet reached an age to be affected by the disease but will
inevitably develop symptoms, the methodological framework
we used was one of survival analysis. In order to make predic-
tions about age at onset, we used a parametric survival model,
namely a log-normal censored model. The age at onset was pre-
dicted from the moment of birth for a patient with known
genotype using the following formulae:
Log(T) ¼ mG þ gGE ð1Þ
where: T is the age at onset from birth, a random variable for a
patient with known genotype, mG is the expectation of Log(T),
gG is the SD of Log(T), and E is a random variable with a stand-
ard Gaussian probability density function.
The mean log age at onset mG, for a given genotype, is
derived from a regression model as follows using the numbers
of repeats of the two alleles ne and nne: expanded and not
expanded respectively:
mG ¼ a0 þ aene þ anenne ð2Þ
where a0, ae and ane are the regression parameters that are
being estimated.
The random variable T (age at onset) has a log-normal prob-
ability density function (pdf) with parameters mG and gG. Thus
its pdf is:
f(t) ¼ 1
tgG
ﬃﬃﬃﬃﬃﬃ
2p
p e
[Log(t)m
G
]2
2g2
G with t . 0 ð3Þ
As an example f(t) is plotted for SCA2 with a repeat number of
the expanded allele of 37 (ﬁgure 1).
When T is censored, we need to express S(t)=P(T>t). We
have:
S(t)=1—F(t), where
F(t) ¼ P(T , t) ¼ P Log(T) mG
gG
,
Log(t) mG
gG
 
¼ F Log(t) mG
gG
 
ð4Þ
And ﬁnally:
S(t) ¼ 1F Log(t) mG
gG
 
ð5Þ
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Estimation of the parameters
The estimation of the parameters was performed using the
affected individuals from the EUROSCA registry whose age at
onset is known, and the unaffected individuals carrying an
expanded allele from the RISCA study. For the latter patients,
the age at last examination was known, and we considered that
this age was a censored value of the age at onset of the disease.
The parameters were estimated by the maximum likelihood
method. Backward selection was used to retain the signiﬁcant
parameter ae or ane. The parameter estimation of the model
was performed using the SAS V9.3 statistical software.
Computation of the predictive statistics: expectation, SD,
and percentiles
In order to take into account that we used parameter estimates,
we added to the variance g2G the variance of m^G, estimated from
the estimated parameters a^0, a^e and a^ne, with
var(m^G) ¼var(a^0 þ ne  a^e þ nne  a^ne)
¼var(a^0)þ var(a^e) n2e þ var(a^ne) n2ne
þ 2 cov(a^0; a^e) ne þ 2 cov(a^0; a^ne)
 nne þ 2 cov(a^e; a^ne) ne  nne
ð6Þ
And ﬁnally:
s^2G ¼ g^2G þ var(m^G) ð7Þ
where, var(a^0), var(a^e) and var(a^ne) are the variances of the esti-
mated parameters a^0, a^e and a^ne respectively (table 1), cov
(a^0, a^e), cov(a^0, a^ne) and cov(a^e, a^ne) are the covariances
between the estimated parameters (see online supplementary
table S1).
We thus computed the predictive statistics from the estimated
pdf of the age at onset, from birth or conditionally that this age
is greater than the current age. The estimated pdf of the age at
onset is given by the formulae:
bf(t) ¼ 1
ts^G
ﬃﬃﬃﬃﬃﬃ
2p
p eð½LogðtÞm^G2=2s^2GÞ ð8Þ
where m^G is given by formula (2) after replacing the parameters
by their estimates and s^2G is given by formula (7).
From these formulae, one can derive the values of the pre-
dictive statistics (expectation E(t), variance var(T), and percen-
tiles tα) of the age at onset distribution. These predictive
statistics are calculated ﬁrst from the moment of birth, without
regard to the actual disease progression of the individual.
We have:
bE(T) ¼ em^Gþ s^
2
G
2 ð9Þ
and
cvar(T) ¼ (es^2G  1)e2m^Gþs^2G ð10Þ
The ath percentile ta is thus obtained from the inverse of F such
as:
bta ¼ bF1(a) ¼ em^Gþs^GF1(a) ð11Þ
In order to account for the fact that any given asymptomatic
individual has reached his current age c without yet being
affected by disease, we thus estimated the age at onset given a
current age (c). As shown in ﬁgure 1, this leads to a truncation
of the log-normal distribution which increases with c. As the
individuals are not observed at birth, but at a current age c, we
need to estimate E(T|T>c), the expectation of T given that the
individual’s age is more than c, the corresponding variance Var
(T|T>c) and the corresponding percentiles tα.
Table 1 Parameter estimates obtained from the parametric
survival model
Parameter
estimate
Parameter
standard
error p Value
SCA1
Intercept 5.4952 0.1924 <0.0001
Expanded allele −0.0487 0.0019 <0.0001
Shorter allele 0.0133 0.0055 0.0151
Standard deviation (γG) 0.1748 0.0069
SCA2
Intercept 7.6301 0.1802 <0.0001
Expanded allele −0.1051 0.0046 <0.0001
Standard deviation (γG) 0.2520 0.0101
SCA3
Intercept 7.4908 0.1853 <0.0001
Expanded allele −0.0564 0.0027 <0.0001
Standard deviation (γG) 0.2167 0.0076
SCA6
Intercept 6.3470 0.2684 <0.0001
Expanded allele −0.0901 0.0091 <0.0001
Shorter allele −0.0285 0.0102 0.0053
Standard deviation (γG) 0.1738 0.0095
SCA, spinocerebellar ataxias.
Figure 1 Conditional probability density function of age at onset for
different current ages (CA) (t). The ﬁgures are drawn for SCA2 data
with a repeat number of the expanded allele of 37 for an individual at
birth (solid), or at a current age of 30 (medium dash), 40 (short dash)
or 45 (short dash dot). Based on a log linear parametric model, the
estimation of the mean age at onset from birth was 43 years (γG:
3.7428,s^G: 0.2516) (vertical dashed line). As the distribution is
log-normal the mode is neither the mean nor the median. SCA,
spinocerebellar ataxias.
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bEcðTÞ ¼ E(TjT . c) ¼ em^Gþðs^2G=2ÞF(ðm^G þ s^2G  LogðcÞ=s^GÞ)
F(ðm^G  LogðcÞ=s^GÞ)
ð12Þ
cvarc(T) ¼ cvar(TjT . c) ¼ bEc(T2) bEc(T)2 ð13Þ
with
bEc(T2) ¼ e2(m^Gþs^2G)F(ðm^G þ 2s^2G  LogðcÞ=s^GÞ)
F(ðm^G  LogðcÞ=s^GÞ)
ð14Þ
And the ath percentile is given by:
bta ¼ exp m^G þ s^GF1 aþ (1 a)F LogðcÞ  m^Gs^G
   
ð15Þ
In this paper, we computed the 5th, 50th (median) and 95th
percentiles of the T pdf. We called the (5th; 95th) interval the
critical region (90% CR).
Model validation
We conducted a validation study in order to assess the
goodness-of-ﬁt of the log-normal model. For each type of SCA
disease, the model’s validation is based upon the comparison of
the observed survival function of the whole sample, as obtained
by the Kaplan-Meier method, and the sample estimated survival
function. The sample estimated survival function was obtained
by the crossover method: for each individual of the sample, the
parameters of the model were obtained by removing the indi-
vidual from the sample, and estimating the survival function of
the individual based on its genotype. The sample estimated sur-
vival function is the mean of these estimated survival functions
for each individual.
Sensitivity analysis
One limitation of our study is that the sample we used was
obtained by merging two samples, one with affected patients
and one with preclinical mutation carriers. As discussed previ-
ously in this paper, while it is crucial to include both affected
and unaffected carriers, the two samples do not have the same
parameters and thus the accuracy of our results may depend of
the respective proportions of the two populations. In order to
study the sensitivity of the results to these proportions, we con-
ducted a sensitivity analysis with the following method: we
modiﬁed the proportions of the two sub-samples by multiplying
the unaffected sample size by the factors 0.5 (half of the
unaffected) and 2 (twice as many unaffected). This was done by
giving these weights to each individual within the preclinical
mutation carrier sample, and by making all computations with
these weighted samples.
RESULTS
Description of the populations
We included 1310 individuals; of these 1187 were EUROSCA
affected individuals (SCA1: 317, SCA2: 308, SCA3: 399, SCA6:
163) from 735 families and the remaining 123 were RISCA
unaffected individuals (SCA1: 50, SCA2: 31, SCA3: 26, SCA6:
16) from 102 families. Forty-two families included both
EUROSCA affected (120 individuals) and RISCA unaffected
individuals (51 individuals). Half of the individuals were males,
and half were females. SCA6 individuals were older than the
individuals from the other genotypes. As expected, within each
genotype, the mean age at last examination for the unaffected
individuals was lower than the mean age at onset of the affected
individuals (SCA1: <0.0001, SCA2: 0.0047, SCA3: 0.0051,
SCA6: 0.0287). However, there was overlap as the age of some
unaffected individuals was higher than the age at onset of some
affected individuals (table 2).
Parametric model
For SCA2 and SCA3 genotypes only the number of repeats of
the expanded allele was signiﬁcantly associated with the age at
onset, while for SCA1 and SCA6 genotypes the number of
repeats of both alleles were signiﬁcantly associated (table 1)
with age at onset. The recruiting centre, family, and year at
onset separated as quartile did not substantially inﬂuence the
results. For all genotypes, gender was not signiﬁcantly asso-
ciated with age at onset, but, as expected, the expanded allele
had a negative effect on the age at onset. For SCA1, the log of
the age at onset decreased by 0.049±0.002 (SE) (p<0.001)
for each additional repeat, for SCA2 by 0.105±0.005 (p <
0.001), for SCA3 by 0.056±0.003 (p<0.001), and for SCA6
by 0.090±0.009 (p<0.001). In addition, in SCA1, the log of
the age at onset increased by 0.013±0.005 (p=0.014) with
each additional repeat on the shorter non-expanded allele, and
in SCA6, the log age at onset decreased by 0.029±0.010
(p=0.0075).
Prediction of age at onset
Based on a log-normal distribution of the age at onset, we
obtained the age at onset for each genotype and the range of
observed repeat lengths within each genotype. For example, an
individual with 37 repeats in the SCA2 gene would have a
median age at onset of 42 years old (90% CR: 28–64) (ﬁgure 1,
see online supplementary table S3). Given that this individual is
unaffected at the age of 35 years, he would have a 50% risk of
developing the disease before the age of 45 years (90% CR: 36–
66) and if he remains unaffected at the age of 45 years, he
would have a 50% risk of onset before the age of 52 years (90%
CR: 46–71) (ﬁgure 2B, see online supplementary table S3).
Similar results were obtained for SCA1 (ﬁgure 2A, see online
supplementary table S2), for SCA3 (ﬁgure 2C, see online sup-
plementary table S4), and for SCA6 (ﬁgure 2D, see online sup-
plementary table S5). For all SCAs, the accuracy of prediction of
the age at onset decreased with the size of the allele expansion:
for those with large repeat expansions prediction was more
accurate compared to those with mildly expanded alleles. In
addition, on average, only 4% of the variance of the age at
onset (from 1% for SCA3 to 10% for SCA6) was due to the
precision of the statistical model estimation, the remaining being
due to population dispersion.
The models were ﬁtted to the observed data (see online sup-
plementary ﬁgure S1). Furthermore, the models were robust
with respect to the proportion of censored data (see online sup-
plementary ﬁgure S2).
DISCUSSION
Using two unique cohorts (the EUROSCA and RISCA cohorts)
comprised of individuals recruited at the same European
centres, examined by the same clinicians and genotyped in the
same centralised laboratory, we were able to estimate the rela-
tionship between the number of CAG repeats and the age at
onset of gait ataxia in the genes corresponding to the four most
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frequent polyglutamine ataxia diseases: SCA1, SCA2, SCA3,
and SCA6.
Disease onset as deﬁned by the onset of gait difﬁculties can
be variable among patients, and may also be variable depending
on the presence of other patients within a given family, as the
other members are likely to pay closer attention to early disease
symptoms. In contrast to other neurodegenerative diseases such
as Huntington’s disease, in SCAs there are no psychiatric
changes or anosognosia that could interfere with the identiﬁca-
tion of onset by the patient or their families. Estimations were
made according to the genotype of the major gene (number of
repeats of the expand allele and additionally, for SCA1 and
SCA6, the number of repeats in the short allele) and according
to the current age of the carrier of an expansion. There are two
events necessary for the disease to develop—the presence of an
abnormal CAG repeat, and advanced age. For the mutation car-
riers with the longest expansions, the oldest age of onset estima-
tions are 1 or 2 years later than the current age. For these
carriers, very few individuals will be unaffected in old age,
therefore estimations of onset at the oldest ages are more theor-
etical than real. The ages at onset estimated in this study were
similar to those observed and were dependent on CAG repeat
length.12 13 In addition, as observed, the estimations’ variability
decreases with the number of repeats, the smaller the repeat the
more accurate the onset estimation. Small but important contri-
butions of the normal polymorphic expansion on the unaffected
allele were identiﬁed in SCA1 and SCA6, but not in SCA2 and
SCA3.3 Similarly to Van de Warrenburg et al, we found a posi-
tive effect of the non-expanded CAG repeat for SCA1 and a
negative effect for SCA6. This result must be conﬁrmed in an
independent cohort, as slightly less than a third of the affected
individuals of the current study were also in the Van de
Warrenburg et al study.
As has been done previously in Huntington’s disease,6–8 we
included both affected and unaffected carriers of the mutation.
If only affected subjects had been used this could have intro-
duced a bias. Healthy carriers of an abnormally expanded
repeat could be different from affected carriers of the same age.
In particular, individuals with abnormal expansions in the range
just above normal size are expected to start the disease late in
life; consequently, they have competing mortality risk and could
die of other diseases before the onset of ataxia. This is particu-
larly relevant for SCA6 which has the latest onset of all SCAs.
Using only data of affected individuals for estimating the inﬂu-
ence of the size of the CAG repeat could lead to a bias provid-
ing unduly pessimistic estimates of age at onset.7 To avoid these
biases, a survival analysis allowed us to take into account the
unaffected but censored individuals. Almaguer-Mederos et al9
published the mean and median age at onset from birth for a
range of CAG expansion sizes in SCA2 mutation carriers from a
Cuban founder population. Compared to their results, our esti-
mates produced a younger age at onset in SCA2. However, the
Cuban estimations were not corrected for the current age of
the patients. Even when we applied the same methodology —
that is, Kaplan-Meier estimates stratiﬁed by repeat length—our
estimations of age at onset were lower for each repeat length
than those in the Cuban population (data not shown). This
may be due to speciﬁc properties of the founder population of
Cuba or to different recruitment strategies. This was also
observed in Huntington’s disease in the Venezuelan population
as reported by the US–Venezuela Collaborative Research
Project and Nancy S Wexler.14 Both the Venezuelan
Huntington cohort and the Cuban SCA sample contained
affected and preclinical carriers, from large families with a
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homogeneous genetic background. Their results could be due
partly to a speciﬁcity of the population, for example, a modi-
ﬁer gene or an environmental effect present in the Cuban
population but absent from our study sample population. The
samples of our study were recruited in a two-step procedure:
ﬁrst, the affected subjects, and then, their unaffected relatives
without systematic screening of the families. Because of this,
there may be some carriers within these families with subclin-
ical signs that were not included in either the affected or
unaffected cohorts. This could have led to pessimistic estima-
tions of onset age as not all unaffected expansion carriers are
necessarily included. Conversely, we have shown that the inclu-
sion of some additional unaffected carriers would have only a
small impact on the estimations.
The range of repeat lengths did not cover the entire range
that has been previously published. Thus, our results are only
valid and usable within this smaller range. An extrapolation
outside the range of observed repeats would be misleading. In
addition, the present results need to be conﬁrmed either in a
replication cohort, or by longitudinal data. These data are not
currently available. In addition, the subjects included in the
EUROSCA and RISCA cohorts are of primarily European
origin. Thus, the extension of the results to other geographical
origins must be done cautiously.
Both the SDs of age at onset and the critical regions of the
predicted ages—the interval where we have a 90% chance to
have the observed age—were quite large. Most of the estimated
age variance comes from age dispersion within the population,
so it cannot be signiﬁcantly decreased by a larger sample size.
The use of these estimates for clinical purposes, particularly in
the context of predictive testing, must be done very carefully,
taking into account the variability of the estimates. Keeping
these limitations in mind, the estimations can be of help when
counselling presymptomatic carriers for the patient that requests
it. One risk of this kind of use could be that the knowledge of
one’s expected age at onset might induce an earlier onset for
carriers that are aware of their genetic status. However, data
from Huntington’s disease do not seem to conﬁrm this kind of
effect. In a cohort of presymptomatic Huntington carriers,
knowledge of one’s genetic status after presymptomatic testing
did result in increased auto-observation, but the onset of this
disease has always been difﬁcult to deﬁne for the carrier and the
care taker, as psychiatric symptoms and anosognosia can compli-
cate the determination of disease onset.15 In the case of SCAs
this estimation could be more accurate as anosognosia is not
present in this disease. In addition, the estimates can be used for
epidemiological purposes—for example, to correlate the time to
onset to a particular clinical phenotype such as the score on a
disease rating scale or to associated phenotypes such as cerebral
imaging results. Knowing the expected age at onset in preclin-
ical individuals, Jacobi et al10 were able to infer that for SCA1
and SCA2 mutation carriers the extent of functional and brain
structural alterations increased as the interval to the predicted
age of ataxia onset decreased.
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